Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	13.06	6.28	5.85	5.5	4.77
Research & Development	75.06	1.01	4.75	13.83	4.99
Operating Expenses	88.12	7.3	10.6	19.34	9.77
Operating Income	-88.12	-7.3	-10.6	-19.34	-9.77
Interest Expense / Income	1.47	0	0	0	0.01
Other Expense / Income	-5.87	-1.96	-0.67	-0.01	-0.03
Pretax Income	-83.72	-5.34	-9.93	-19.32	-9.75
Income Tax	0	0	0	0	-0.01
Net Income	-83.72	-5.34	-9.93	-19.32	-9.74
Shares Outstanding (Basic)	17	1	1	1	0
Shares Outstanding (Diluted)	17	1	1	1	0
Shares Change	1297.57%	0.04%	3.64%	195.18%	256.50%
EPS (Basic)	-3.87	-4.44	-8.28	-16.68	-24.84
EPS (Diluted)	-3.87	-4.44	-8.28	-16.68	-24.84
Free Cash Flow	-58.03	-5.01	-10.91	-18.81	-7.74
Free Cash Flow Per Share	-3.46	-4.17	-9.09	-16.23	-19.73
Dividend Per Share	19.356	-	-	-	-
EBITDA	-82.1	-5.23	-9.81	-19.23	-9.65
Depreciation & Amortization	0.15	0.11	0.11	0.09	0.09
EBIT	-82.26	-5.34	-9.93	-19.32	-9.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).